Within Discredited Stem Cell Research, a True Scientific First
By Nicholas Wade,
New York Times
| 08. 03. 2007
The world of stem cell research was set reeling two years ago when its most successful practitioner, the Korean scientist Hwang Woo Suk, was found to have fabricated much of his work. But according to a new post-mortem of his research, he did achieve a scientific first, though not the one he claimed.
Dr. Hwang said he had derived embryonic stem cells from the adult cells of a patient, but the claim was discredited after parts of his research were found to have been faked. A team of Boston scientists has now re-examined stocks of Dr. Hwang's purported embryonic stem cells and arrived at a surprising conclusion: His embryonic stem cells were the product of parthenogenesis, or virgin birth, meaning they were derived from an unfertilized egg.
A team led by Kitai Kim and George Q. Daley of Children's Hospital Boston reports this conclusion today in the journal Cell Stem Cell.
Embryonic stem cells derived through parthenogenesis cannot develop normally, so they are free of ethical objections. The cells could perhaps help treat degenerative diseases in women capable of...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
